Omid Veiseh, Rice Biotech Launch Pad Faculty Director, Inducted into American Institute for Medical and Biological Engineering (AIMBE) College of Fellows
HOUSTON, April 2, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures, announced today that Omid Veiseh, the Launch Pad's faculty director and professor of bioengineering at Rice University, was inducted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows for 'advancement of cell-based therapeutics toward developing transformative medicines for treating cancer, metabolic diseases, Type-1 diabetes, and inflammatory disorders.'
Dr. Veiseh's induction ceremony took place Monday, March 31, at 10:45 a.m. ET at the Renaissance Capital View Hotel in Arlington, VA, during the AIMBE Annual Event. His induction included 171 additional colleagues who joined him in forming the AIMBE College of Fellows Class of 2025. Dr. Veiseh was nominated, reviewed, and elected by peers and members of the College of Fellows.
'I am deeply grateful to my colleagues who elected me to the prestigious AIMBE College of Fellows,' said Dr. Omid Veiseh, faculty director of the Rice Biotech Launch Pad and professor of bioengineering at Rice University. 'This recognition reflects the collective efforts of our research team and collaborators down in Houston in developing innovative cell-based therapeutics. Not only does this acknowledge our progress, but it also serves as a motivation to further advance transformative medicines through the Launch Pad, with the goal of meaningfully impacting the lives of patients worldwide.'
AIMBE Fellows are among the most distinguished medical and biological engineers, including 4 Nobel Prize laureates and 27 Presidential Medal of Science and/or Technology and Innovation awardees. Additionally, 233 Fellows have been inducted to the National Academy of Engineering, 120 inducted to the National Academy of Medicine, and 51 inducted to the National Academy of Sciences. For more information about AIMBE, please visit www.aimbe.org.
About the Rice Biotech Launch Pad:
The Rice Biotech Launch Pad is a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures. This initiative is designed to help advance internally discovered platform technologies from concept to clinical studies and commercialization. The Rice Biotech Launch Pad will identify and support highly differentiated projects while driving the expansion of Houston as a world-class medical innovation ecosystem. The accelerator will bring together local researchers with a network of industry executives. For more information, please visit https://biotechlaunchpad.rice.edu/.
About Rice:
Located on a 300-acre forested campus in Houston, Texas, Rice University is consistently ranked among the nation's top 20 universities by U.S. News & World Report. Rice has highly respected schools of architecture, business, continuing studies, engineering and computing, humanities, music, natural sciences and social sciences and is home to the Baker Institute for Public Policy. Internationally, the university maintains the Rice Global Paris Center, a hub for innovative collaboration, research and inspired teaching located in the heart of Paris. With 4,776 undergraduates and 4,104 graduate students, Rice's undergraduate student-to-faculty ratio is just under 6-to-1. Its residential college system builds close-knit communities and lifelong friendships, just one reason why Rice is ranked No. 1 for lots of race/class interaction and No. 7 for best-run colleges by the Princeton Review. Rice is also rated as a best value among private universities by the Wall Street Journal and is included on Forbes' exclusive list of 'New Ivies.'
About AIMBE
AIMBE is the authoritative voice and advocate for the value of medical and biological engineering to society. AIMBE's mission is to recognize excellence, advance public understanding, and accelerate medical and biological innovation. No other organization brings together academic, industry, government, and scientific societies to form a highly influential community advancing medical and biological engineering. AIMBE's mission drives advocacy initiatives into action on Capitol Hill and beyond.
Media Contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
3 hours ago
- Indianapolis Star
FDA: More cucumbers, ready-to-eat products recalled in growing salmonella outbreak
A Maryland food company has recalled specific salsa and cucumber products because they were made with cucumbers that are possibly contaminated with salmonella. TGD Cuts, LLC of Jessup, Maryland, is recalling some tub and tray products because they contained cucumbers from Boynton Beach, Florida-based Bedner Growers Inc., which have been linked to a salmonella outbreak. TGD Cuts distributed the affected products, which included salsas, sliced cucumbers and cucumber spears, to retail and foodservice locations in Maryland, Virginia, Pennsylvania, New Jersey, and North Carolina, according to the Food and Drug Administration (FDA). The products had use-by dates ranging from May 20 to May 28 and are unlikely to be in stores or being used. No illnesses have been reported in connection with the products, the FDA said. Egg recall: Brown eggs sold at some Walmart stores have salmonella risk The initial May 19 recall involved cucumbers sold directly to consumers at Bednar's Farm Fresh Market, according to notices published May 19 by the Centers for Disease Control and Prevention (CDC) and the FDA. Subsequent recalls have been announced by grocers such as Harris Teeter, Kroger and Walmart for repackaged cucumbers for resale under different brand names or those used in ready-to-eat products, including vegetable trays and salads. The cucumbers, distributed by Fresh Start Produce Sales of Delray, Florida, also led to Target recalling individual cucumbers on May 30, specifically cucumber two-packs and various prepared foods products. In addition to the growing cucumber-related recall, other products have been recalled recently for potential salmonella contamination. The FDA on May 28 upgraded a recall of tomatoes distributed in three southern states to a Class I recall, meaning consumption of the food could cause serious health complications or lead to death. Then, on June 6, the CDC and FDA linked brown eggs sold in nine states – including at some Walmart stores – to an ongoing Salmonella Enteritidis outbreak, in which 79 people have been sickened and at least 21 hospitalized. Customers who purchased any products from TGD Cuts should get rid of them or return them for a full refund. Here is the list of products recalled due to a possible salmonella risk. Salmonella poisoning causes about 1.35 million illnesses, 26,500 hospitalizations, and 420 deaths each year in the U.S., according to the CDC and FDA. Symptoms, which include diarrhea, fever and stomach cramps, will usually occur six hours to six days after exposure and may last up to seven days. Symptoms from severe infections may include aches, headaches, elevated fever, lethargy, rashes, and blood in urine or stool. Mike Snider is a reporter on USA TODAY's Trending team. You can follow him on Threads, Bluesky, X and email him at mikegsnider & @ & @mikesnider & msnider@
Yahoo
5 hours ago
- Yahoo
Chris Hadfield: ‘Worst space chore? Fixing the toilet. It's even worse when it's weightless'
What's the most chaotic thing that's ever happened to you in space? Launch – you go from no speed at all to 17,500 miles an hour in under nine minutes. The chaos is spectacular, the power of it is just wild, the physical vibration and force of it is mind-numbing – and it all happens so blisteringly fast. In the time it takes to drink a cup of tea, you go from lying on your back in Florida to being weightless in space. It's just the most amazing, chaotic, spectacular, rare human experience I've ever had. As an astronaut you have to master so many skills; have you ever not known something in space and wished you did? Onboard a spaceship, if you have an electrical problem, an attitude control problem, a propulsion problem, a computer problem – one of the first things you lose is communications with Earth. So it's really important to have all the skills on board. I served as an astronaut for 21 years and I was only in space for six months – that gave me 20-and-a-half years to not have to be surprised or flummoxed while I was in space. Related: Alan Davies: 'I get called Jonathan Creek all the time – nowadays people think I'm James May' As an example, I qualified as an emergency medical technician. I worked in the cadaver lab [of Hermann hospital in Houston, near Nasa] to get familiar with the human body and then I worked in all of the wards of the hospital. I assisted a surgeon who was doing full abdominal surgery on an accident victim and then I worked in emergency, doing all the immediate triage. I had to get all of those skills just in case we had a medical problem on the spaceship. We take preparation really seriously so that we won't just be tourists up there. You've written six books; which book or author do you always return to? It depends which book I'm writing. I've written three nonfiction and three thrillers, and when I'm writing thriller fiction I tend to read that, because it gets your mind in the groove. I have lots of favourite thriller authors – Robert Ludlum, John D MacDonald and Jonathan Kellerman … I go back and read those, study how they make you feel so compelled. What about favourite sci-fi? [Growing up] I read Asimov and Arthur C Clarke. I got to spend a day with Arthur C Clarke – he came to the Kennedy Space Centre, I spent a whole day showing him the space shuttle and the launch site, and it was like a dream come true because he'd been one of my science fiction idols growing up. [In 2015] Ray Bradbury's family asked me to write an introduction for the Folio Society rerelease of The Martian Chronicles – I'd read it once a long time ago but I'd forgotten just what an exquisitely good writer he was. The Martian Chronicles was written just after the second world war, so after the first two atomic bombs had been released and killed so many people but before the very first space flight. It was a really interesting moment in time – of both despair and disgust at human behaviour and then hope. And it's a beautiful book. How likely do you think it is that there is intelligent life in space? We have found no evidence but we know that every star has at least one planet, and our telescopes are so good now that we can actually find how many of those planets are close enough to Earth that they could support life as we know it, and it's around 5%. And so if 5% of every planet could sustain life, we can count the stars in the universe and [estimate] how many planets there are that could sustain life. And the number is staggeringly huge – it's like a quintillion of planets. So the odds are overwhelming that there's got to be life in other places … [But] it was only quite recently that life on Earth evolved – through time and chance – into multi-cellular life, and then complex life, and then to be self-aware and have intelligence. My conclusion is that life will be common: we'll find slime and scum all over the place. But intelligent life I think is exquisitely rare and I think we should internalise that and think about the level of responsibility that we should adopt. What's your favourite space movie? 2001: A Space Odyssey. I just find it fascinating and intriguing and a beautiful Stanley Kubrick adaptation of Arthur C Clarke's vision of things. It's very thought-provoking even almost 60 years later. I think The Martian is a very good movie and the Andy Weir book [it's based on] – I love that. I think Ron Howard did a beautiful job with Apollo 13 – it's almost a documentary. He worked so hard, he spent time with the astronauts, he filmed in a zero G aeroplane. Tell us your favourite fact. The most experienced astronaut in all of American history is a woman named Peggy Whitson. She's flown in space multiple times [and] been longer in space than any other American. She's commanded the space station twice. She's done 10 spacewalks and she's been the chief astronaut for Nasa. She's a tour de force. She's a good friend. She's a great person. Do you have a party trick? I'm a musician, I play guitar and sing – and I have the type of head that remembers lyrics. So my party trick is that I have probably 500 songs that I can play at any moment and know every single word and every single chord all the way from the start to the finish. It's just the way my brain works. It's kind of silly but it's really fun to be a human jukebox and have people say, 'Hey, can you play that song?' When I'm on stage in Australia, I'll have a guitar and I'll play a few songs. What's the worst space chore? Fixing the toilet. They break all the time. Being elbows deep in a toilet anywhere is no fun – it's even worse when it's weightless. And the trouble with our toilets is they have really nasty, poisonous chemicals and filters in them to try and process what's going through so that we can turn our urine and sweat back into drinking water, because we recycle about 93-94% of the water on board. Related: The Superjesus' Sarah McLeod: 'Everyone should have a nemesis' What's the best lesson you learned from someone you've worked with? We were in the space shuttle simulator [with commander Kent Vernon 'Rommel' Rominger] and one of the crew members, Scott, had this cool and exciting idea. He came ripping up to the cockpit and plunked his laptop down to show him the solution to the problem and he knocked over Rommel's can of Coke – it flipped upside down and started emptying itself into all of his checklists. Rommel turned the can right side up and didn't say a thing. What this guy had come up with would be hugely important in the success of our mission. A little Coke spilled is unimportant – you can get more checklists. The natural reaction would have been, 'What the heck are you doing? Don't be so clumsy and look at the mess you made.' Instead, Rommel was like, 'Who cares? What I don't want Scott to think about next time he's got a great idea is, 'Oh, I gotta be careful I don't spill the commander's Coke.'' He should be excited about new ideas. And so, for me, it was a really great study of leadership. What song do you want played at your funeral? Danny Boy. It's a lovely reversal of how people normally look at death and who's grieving and why, and how you anticipate the grieving of death. It is an exquisitely and hauntingly beautiful song, and it's worth knowing the lyrics. Chris Hadfield's Journey to The Cosmos is touring Australia: Perth (27 June), Sydney (28 June), Brisbane (29 June), Melbourne (1 July) and Adelaide (3 July)
Boston Globe
7 hours ago
- Boston Globe
Will Trump's policies kill Massachusetts' life sciences leadership?
Advertisement Although the industry is centered in eastern Massachusetts, there's a statewide benefit from all the tax dollars those businesses and workers pay. Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up In all, Massachusetts organizations — including universities, research institutes, and hospitals — received $3.5 billion in funding from the National Institutes of Health. Massachusetts-headquartered companies raised $3.26 billion in venture capital funding. Among all drugs in the development pipeline in the United States, 15 percent were being made by companies headquartered in Massachusetts. But actions taken by President Trump and his administration — cutting funding for scientific research and universities, flirting with tariffs, fanning skepticism about vaccines — threaten to devastate the ecosystem. Today, the industry is at a precipice, and uncertainty abounds. Some companies are already feeling the pinch of terminated federal grants, while others are anxious about what might come. Taken together, Trump's policies could force some companies and scientists to take their money, talents, and products overseas. Advertisement Christopher Locher, CEO of Lowell-based Versatope Therapeutics, which develops a platform to deliver vaccines and therapeutics, said he worries the Greater Boston life sciences ecosystem is 'being flushed down the toilet.' For example, Trump is Trump's funding cuts are already having a large impact on some local companies. Part of the problem is the Trump administration isn't only cutting funding, but it's picking which technologies to fund — in some cases apparently based on politics more than science. Take flu vaccines. The Trump administration recently announced a $500 million campaign to fund the development of a universal flu vaccine, which doesn't require annual updates, using technology being worked on But simultaneously, he cut funding for other work on a universal flu vaccine. Versatope Therapeutics got $14 million in NIH funding and spent five years developing a universal flu vaccine. It had approval from the US Food and Drug Administration to begin clinical trials when Trump terminated the contract's remaining $8 million, with the reason given being 'convenience,' Locher said. Trump also Advertisement Company executives say decisions by Trump officials to disinvest in vaccine-related technology — and concerns about whether government will approve new technology — means it's nearly impossible to find private investment funding to replace lost federal dollars. 'We're faced with bankruptcy in the very near future,' Locher said. Ironically, given Trump's stated commitment to bringing businesses back to the United States, one potential option Locher is eyeing is opening a subsidiary abroad. Conducting clinical trials would be cheaper in another country, whether in Europe, Australia, or China, Locher said, and some countries are offering financial incentives to American companies to relocate. Companies also face a potential workforce brain drain. There have been MassBio officials said China has less rigorous — but faster — safety and research protocols than the US. Australia allows a faster timeline for clinical trials. If regulatory approval of medicines is held up because the FDA is understaffed, companies may seek European regulatory approval instead. The loss of talent to foreign countries will be compounded if the pipeline of local university graduates dries up. One draw for life sciences companies to Boston/Cambridge is the presence of elite schools like Harvard and MIT, with their potential for faculty collaboration and skilled graduates. Advertisement Trump is trying to Chip Clark, CEO at Vibrant Biomedicines in Cambridge, said cuts to university research funding both 'shrink the pipeline of great ideas' that form the basis for many biotech startups and translate to fewer available scientists. Clark said the administration's policies 'seem like a deliberate attempt to try to cede scientific leadership to Europe and Japan and Korea and China. ... They will be delighted to capitalize on our talent, technology, and investment capital to make their robust biotech sectors grow and ultimately compete successfully against the US industry,' he said. Don Ingber, founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, said he has postdocs with US visas applying for jobs in Europe, and others who were accepted to work at Harvard but are going elsewhere. 'The fact that places like Harvard and MIT and American universities are magnets for the best and brightest from around the world is what's driven our technology economy and certainly the Boston/Cambridge ecosystem,' Ingber said. 'With this uncertainty, I fear we'll lose a generation.' Ingber, who was forced to stop work on two government-funded projects on drugs designed to prevent injury from radiation exposure, compared administration policies to 'eating seed corn' needed to grow crops. Advertisement Trump's vendetta will undermine one of the most vibrant state economies in the country and set back American science by years. And it's not just eastern Massachusetts that will pay a price; the entire country will. As Ingber noted, it might take years to see the impact of medicines or technologies that aren't developed because of these shortsighted cuts. Editorials represent the views of the Boston Globe Editorial Board. Follow us
